Clinical Research Directory
Browse clinical research sites, groups, and studies.
Micro-Ultrasound for Detecting Clinically Significant Prostate Cancer in Active Surveillance
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Summary
Active surveillance is a common approach for men with low-risk or favorable intermediate-risk prostate cancer, aimed at avoiding or delaying treatment while closely monitoring the disease. Multiparametric MRI (mpMRI) is widely used to guide diagnosis and follow-up, but it can miss clinically significant prostate cancer and may be limited by access, cost, and variability in interpretation. Micro-ultrasound is a high-resolution ultrasound technique that may improve real-time detection of suspicious prostate lesions using a standardized scoring system (PRI-MUS). The purpose of this study is to evaluate the diagnostic performance of micro-ultrasound for detecting clinically significant prostate cancer in men with negative or stable mpMRI findings, either at initial diagnosis or during active surveillance follow-up. Participants will undergo micro-ultrasound assessment of the prostate. Areas considered suspicious on micro-ultrasound may be targeted for biopsy, followed by systematic prostate sampling. Biopsy results will be used as the reference standard to determine whether clinically significant prostate cancer is present. The study will assess measures such as sensitivity, specificity, and predictive values of micro-ultrasound, as well as procedure-related complications.
Official title: Evaluating Micro-Ultrasound as a Supplemental Imaging Modality for Clinically Significant Prostate Cancer Detection in Men With Negative or Stable Multiparametric MRI on Active Surveillance or at Diagnosis
Key Details
Gender
MALE
Age Range
45 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
90
Start Date
2026-03-01
Completion Date
2027-06-01
Last Updated
2026-02-04
Healthy Volunteers
No
Interventions
Micro-Ultrasound (mUS)
High-frequency micro-ultrasound prostate imaging with real-time lesion assessment. Targeted biopsy of suspicious lesions will be performed when present, along with concurrent systematic 12-core biopsy.
Locations (1)
Jewish General Hospital
Montreal, Quebec, Canada